Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opthea Ltd ADR (NQ: OPT )

3.454 +0.034 (+1.01%)
Streaming Delayed Price Updated: 9:48 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Opthea Ltd ADR

Opthea to Receive US$35M Commitment and Additional US$50M Funding
From Opthea Limited
Via GlobeNewswire
Opthea Receives A$8.8 million R&D Tax Incentive
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the FLORetina 2023 Congress
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the Jefferies 2023 London Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
From Opthea Limited
Via GlobeNewswire
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
From Opthea Limited
Via GlobeNewswire
Opthea to Participate at the 2023 Euretina Congress
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Opthea Limited
Via GlobeNewswire
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
From Opthea Limited
Via GlobeNewswire
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the 2023 Ophthalmology Innovation Summit
From Opthea Limited
Via GlobeNewswire
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
From Opthea Limited
Via GlobeNewswire
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
From Opthea Limited
Via GlobeNewswire
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the Jefferies 2023 Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
From Opthea Limited
Via GlobeNewswire
Opthea To Present at the JMP Securities Life Sciences Conference
From Opthea Limited
Via GlobeNewswire
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
From Opthea Limited
Via GlobeNewswire
Opthea Receives A$8.7 million R&D Tax Incentive
From Opthea Limited
Via GlobeNewswire
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
From Opthea Limited
Via GlobeNewswire
Opthea To Present at SVB Leerink Global Biopharma Conference
From Opthea Limited
Via GlobeNewswire
Opthea To Present at Sequire Biotechnology Conference
From Opthea Limited
Via GlobeNewswire
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
From Opthea Limited
Via GlobeNewswire
Opthea to Present at the FLORetina 2022 Congress
From Opthea Limited
Via GlobeNewswire
Opthea to Present at Jefferies London Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
From Opthea Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.